OPGEN (OPGN) Company Report

Analyst Earnings Quarterly Reports

Earnings summaries and quarterly performance for OPGEN.

Research analysts covering OPGEN.

Recent press releases and 8-K filings for OPGN.

OpGen completes acquisition of Sun Investment Enterprises Limited

OPGN

M&A

New Projects/Investments

OpGen, Inc. completed the acquisition of Sun Investment Enterprises Limited on December 1, 2025, which makes iCapX Sdn. Bhd., a cap table management fintech platform, an indirect, wholly-owned subsidiary of OpGen.
The purchase price for the acquisition was $12,278,703.08, which OpGen will satisfy by issuing 2,028,867 shares of common stock at a price of $6.052 per share to the seller, AEI Capital Ltd., OpGen's controlling stockholder.
Following the acquisition, OpGen recognized an advisory fee from a client, consisting of $80,000 and 1.4% of the client's outstanding equity, which is estimated to be valued at approximately $14 million.

Jan 16, 2026, 9:15 PM

Opus Genetics Highlights 2025 Progress and Upcoming 2026 Catalysts

OPGN

Guidance Update

New Projects/Investments

Product Launch

Opus Genetics reported $30.8 million in cash and cash equivalents as of September 30, 2025, with a total cash position of over $50 million after a subsequent equity offering, which is expected to fund operations into the second half of 2027.
The company anticipates 3-month results from Cohort 1 of the OPGx-BEST1 Phase 1/2 trial in mid-2026 and expects to begin dosing OPGx-LCA5 in its pivotal Phase 3 trial in the second half of 2026.
A Supplemental New Drug Application (sNDA) for Phentolamine Ophthalmic Solution 0.75% for presbyopia has been submitted, with an anticipated regulatory decision by the end of 2026, and topline results for the LYNX-3 trial are expected in the first half of 2026.